IBM announced solid Q1 2024 results, but the stock is down in after-hours trading. While the decline isn't as severe as Meta's, it's likely due to conservative expectations for the future. The company is guiding for single-digit revenue growth. Shares are down about 6% in after-hours trading.
Key takeaways:
Start investing today or test a free demo
Open real account TRY DEMO Download mobile app Download mobile app- Revenue: $14.46 billion (up 1% YoY, 3% at constant currency) - in line with market expectations ($14.25 billion)
- Earnings per share (EPS): $1.68 (above expectations: $1.59)
- Software revenue: $5.90 billion (up 5%, 6% at constant currency)
- Consulting revenue: $5.19 billion (up slightly, 2% at constant currency)
- Free cash flow: $1.91 billion (up $0.6 billion)
- Margins: Strong margin improvement (GAAP gross margin: 53.5%, Non-GAAP operating margin: 54.7%)
- Full-year guidance: Maintaining revenue in the single-digit growth range and free cash flow of around $12 billion
Additional information from the company:
- IBM reiterated its intention to acquire HashiCorp for $6.4 billion, which will strengthen its hybrid cloud offerings.
- The company emphasized the strength of its hybrid cloud and artificial intelligence (AI) strategy.
- IBM's WatsonX and generative AI businesses are showing strong growth, with contract value already exceeding $1 billion since WatsonX's launch in mid-2023.
IBM started 2024 with solid financial results, confirming the effectiveness of its strategy, but at the same time, it's not indicating significant growth. The acquisition of HashiCorp is expected to strengthen the company's hybrid cloud offerings, but it could also signal some attempts to stimulate more growth in the future.
IBM shares are down about 6.5% in after-hours trading, erasing all the gains from the Q4 earnings report, similar to Meta.
Source: xStation5
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.